Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck (MRK) stock gains as new oral HIV tablet matches Gilead's (GILD) three-drug once-daily HIV pill Biktarvy in a Phase 3 ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...